Drug intelligence / Profile preview

67Cu-NuriPro

Development stage: Preclinical
Lead developer: Nuclidium
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

67Cu-NuriPro is a copper-67 labeled radiopharmaceutical designed for the targeted treatment of prostate cancer. It consists of copper-67 chelated to NODAGA and conjugated to PSMA I&T, enabling it to specifically bind to Prostate Specific Membrane Antigen (PSMA), a well-established biomarker highly expressed in prostate cancer cells. As part of Nuclidium's NuriPro theranostic program, this agent is the therapeutic counterpart to the diagnostic imaging agent 61Cu-NuriPro. The mechanism involves delivering beta-emitting radiation directly to PSMA-expressing tumor cells, aiming for precise and effective ablation of malignant tissue while sparing healthy tissue. As of June 2025, 67Cu-NuriPro has completed preclinical development with plans for a phase I clinical trial in patients with prostate cancer[2][3][5][6].

Brand names: 67Cu-NuriPro
Other names: 67Cu-NODAGA-PSMA I&T

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on 67Cu-NuriPro.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 67Cu-NuriPro.

Explore the full profile